AC Immune Links with Piramal Imaging To Advance Alzheimer’s Research
This article was originally published in The Pink Sheet Daily
Selecting the right patients for clinical trials of potential Alzheimer’s disease therapies could be easier if an agreement on the development of a PET-based diagnostic between the companies bears fruit.
You may also be interested in...
Piramal is working on what it claims is a well-rounded strategy for an international edge in the field of neuroimaging research. While it is adding newer tracers for detection of the root causes of Alzheimer’s disease, its first approved product Neuraceq is ready to hit the U.S. and European markets later this year.
The Swiss biotech raises $22 million in a Series D from its existing private investors to support its research into Alzheimer’s disease therapies.
Piramal steadily carving out a pipeline that will give it a niche in the global pharma business.